Seeking Alpha

GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with...

GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with chronic obstructive pulmonary disease. GSK, which plans to begin filing for regulatory approval at the end of the year, hopes LAMA/LABA will be a successor to Advair. GSK is developing the drug with Theravance (THRX), whose shares are +8%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs